Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01364441 · ClinicalTrials.gov registry record · Phase 1
Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects
A Phase 1 study, sponsored by Ono Pharma USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT01364441 is a Phase 1 study that has completed, run by Ono Pharma USA. The registered enrollment target is 48 participants.
The verdict
NCT01364441, a Phase 1 study, has completed, sponsored by Ono Pharma USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of ONO-2952 across ascending single doses in healthy adult male and female subjects. The secondary objective is to characterize the pharmacokinetic (PK) profile of ONO-2952. The tertiary objective of this study is to preliminarily evaluate the effect of a meal upon the PK profile of ONO-2952.
Interventions
- DRUG Placebo
- DRUG ONO-2952
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2011-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01364441
The ClinicalTrials.gov registry entry for NCT01364441 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ono Pharma USA, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01364441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01364441 about?
NCT01364441 is a clinical study titled "Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects". The primary objective of this study is to evaluate the safety and tolerability of ONO-2952 across ascending single doses in healthy adult male and female subjects. The secondary objective is to characterize the pharmacokinetic (PK) profile of ONO-2952. The tertiary objective of this study is to prel...
What is the current status of trial NCT01364441?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2011-05.
What interventions are being tested in trial NCT01364441?
The interventions under investigation include: Placebo (DRUG), ONO-2952 (DRUG).
Who is sponsoring clinical trial NCT01364441?
This trial is sponsored by Ono Pharma USA, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.